Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
patisiran
5
×
alnylam pharmaceuticals
boston
clinical trials
fda
national top stories
onpattro
akcea therapeutics
drugs
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
pfizer
rna interference
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
anylam pharmaceuticals
biotech
boehringer ingelheim
cardiomyopathy
craig mello
deals
dicerna pharamceuticals
european medicines agency
givosiran
harvard pilgrim health care
hepatitis b
hepatitis b virus
institute for clinical and economic review
What
drug
5
×
alnylam
fda
medicine
pharmaceuticals
rnai
ago
approved
disease
gene
interference
medicines
protein
rna
afternoon
akcea
alnylam’s
amyloidosis
approval
approves
attr
available
battle
caught
causing
cells
debilitating
dicerna
ema
employ
europe
eye
follows
genetic
gets
harmful
hepatitis
history
hits
indicated
Language
unset
Current search:
patisiran
×
drug
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug